MET — MetLife, Inc.

Market sentiment is upbeat after Q2 2026 adjusted EPS of $2.43 beat consensus and rose roughly 20% year over year, helped by Group Benefits and Retirement & Income Solutions momentum. Management added a $3B share repurchase authorization, dividend hikes earlier in 2026 continue to support the income case, and analysts maintain a Buy rating with recent target bumps at JPMorgan and KBW to $108. The stock has been strong YTD and is trading in the upper end of its 52-week range.

The reported GAAP quarterly numbers are noisy. Revenue and GAAP EPS swing materially due to investment mark-to-market, and there is a huge Q4 2025 revenue spike to $23.8B versus a typical $16-19B quarter that the data flags as likely acquisition/divestiture distortion. Cleaner operating trends are better: Q2 2026 adjusted EPS rose ~20% YoY to $2.43, Q1 2026 EPS was strong at $1.74, and 2026 operating cash flow has stayed robust. GAAP operating margins have been choppier and generally lower in 2025-26 (roughly 5-8%) than the 7-11% seen in mid-2024, reflecting investment volatility and medical/underwriting cost pressure rather than a structural collapse in the franchise.

On trailing GAAP EPS of $5.56, MET's 18.3x P/E is slightly above its own 5-year average of 17.2x, but that GAAP number is depressed by investment losses. On the next-fiscal-year adjusted EPS estimate around $9.98, the forward P/E is roughly 9.6x. Price/sales of 0.79x is essentially in line with the 5-year average of 0.78x, and P/B of 2.3x is reasonable for a ~12% ROE. Overall, valuation looks fair on an operating-earnings basis and slightly optically expensive on reported GAAP earnings.

The market is paying about $96 for roughly $10 of forward adjusted operating EPS and a 12% ROE, which is not pricing in aggressive growth. If adjusted EPS delivers as analysts expect and the $3B buyback reduces share count, the stock has room toward the $101-108 consensus target zone. If GAAP net income remains burdened by derivative and investment losses, the headline P/E will stay optically high and could cap near-term multiple expansion despite solid operating fundamentals.

As of 2026-08-27, RSI(14) is 54.24, so the stock is neither overbought nor oversold. Price sits 0.22% below its 20-day SMA, 3.41% above its 50-day SMA, and 18.25% above its 200-day SMA, indicating an intact uptrend with a slight short-term pause. This is a constructive technical backdrop; a pullback toward the 50-day would offer a better entry than chasing strength at these levels.

• Elevated long-term Treasury yields lift reinvestment income on MET's fixed-income portfolio, a net tailwind for net investment income and spread margins.
• Rate volatility around long-end yield spikes creates mark-to-market swings in AOCI and GAAP earnings, even when operating earnings are stable.
• Medical cost inflation remains a headwind in Group Benefits, but MET's diversification into RIS, Asia, and Latin America dilutes the impact.
• Pension-risk-transfer demand stays strong as corporate funded statuses improve at high rates, supporting Retirement & Income Solutions growth.
• Strict NAIC/RBC capital requirements favor well-buffered insurers; MET's holding company liquid assets of ~$3.9B are at the top end of its target range.

• Q3 2026 earnings scheduled for November 4, 2026, with updates on the new $3B buyback and operating momentum.
• Continued integration of PineBridge/MIM, which should expand asset-management fees and align with the 'New Frontier' efficiency plan.
• New $3B share repurchase authorization and potential further dividend increases.
• Large pension risk transfer deals in the RIS pipeline.
• Favorable moves in long-term rates or credit spreads that boost investment income and underwriting spreads.

• A sharp fall in long-term rates would compress reinvestment yield and weaken pension-risk-transfer economics.
• Sustained equity or credit market volatility can trigger realized losses and derivative-driven GAAP EPS swings.
• Group-benefit medical cost inflation and adverse morbidity/mortality could pressure underwriting margins.
• Regulatory capital changes, such as tougher RBC or group-supervision requirements, could force higher buffers and reduce capital returns.
• Integration risk from the PineBridge acquisition could distract management or miss cost-synergy targets.

MET is a well-capitalized, diversified life insurer with genuine operating momentum — Q2 adjusted EPS up ~20%, a fresh $3B buyback, and supportive rates — but backward-looking GAAP profitability is mediocre and the forward adjusted multiple is fair rather than a screaming bargain. It is a steady compounder with capital-return support, best suited for investors comfortable with insurance accounting noise and modest single-digit earnings growth.

Theoretical fair value is derived by applying a 10.5x price/earnings multiple to the next-fiscal-year adjusted EPS estimate of $9.98, reflecting MET's roughly 12% ROE, mid-single-digit operating EPS growth, 2.4% dividend yield, strong free cash flow, and a modest premium to the current ~9.6x forward adjusted multiple.